<a href="https://www.fiercebiotech.com/biotech/bial-bails-after-parkinsons-fail-axing-asset-over-phase-2-miss" hreflang="en">Bial bails after Parkinson’s fail, axing asset over phase 2 miss</a>
fiercebiotech.com·Jun 9, 2026
Bial has halted the development of its Parkinson's drug BIA 28-6156 after its phase 2b trial failed to meet primary and key secondary efficacy endpoints. This setback significantly impacts Bial's research and development pipeline, as the company has limited other active projects.
Bial's decision to halt the development of BIA 28-6156 after missing key efficacy endpoints in a phase 2b trial highlights the inherent risks and challenges in drug development for Parkinson’s, even when targeting genetic subpopulations. For professionals tracking biotech investments, this underscores the importance of closely monitoring clinical trial outcomes and the necessity of having a diversified R&D pipeline to mitigate setbacks.